Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Experience of detection of HER 2 status of circulating tumor cells in the peripheral blood of patients with HER 2-negative locally advanced breast cancer

Natalia Samaneva; Lubov Vladimirova; Inna Novikova; Irina Mitashok; Tatiana Snezhko; Irina Kornilova;

The study of biological characteristics of CTCs, in contrast to other malignant cells in the primary tumor, suggests new tumor markers with a high predictive value. HER2 overexpression in the tumor leads to enhanced proliferation and angiogenesis and apoptosis regulation disorders. HER2 overexpression in BC was confirmed to be associated with a more aggressive disease course, increased metastatic tumor potential and less favorable prognosis. CTCs were proved to be heterogeneous, as their phenotypic and genotypic characteristics can differ from the primary tumor cells. Taking into account the data of numerous studies, we performed a comparative analysis of biological characteristics of primary tumors and CTCs depending on the presence of HER2/neu receptor expression in patients with locally advanced breast cancer. The study demonstrated that CTCs often differ from primary tumor cells in their biological characteristics; in particular, HER2/neu positive CTCs were obtained from the peripheral blood of patients with HER2-negative primary tumors.


1. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell. 2000;100(1):57-70. https://doi.org/10.1016/j.cell.2011.02.013
2. Park D. I., Yun J. W., Park J. H. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 2006;51:1371-1379. https://doi.org/10.1007/s10620-005-9057-1
3. Wallwiener M., Hartkopf A. D., Riethdorf S., Nees J., Sprick M. R. [et al.]. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer. 2015;15:403. https://doi.org/10.1186/s12885-015-1423-6
4. Samaneva N. Yu., Vladimirova L. Yu., Novikova I. A., Mitashok I. S., Shatova Yu. S., Snezhko T. A., Ezhova M. O., Selyutina O.N. Sovremennye problemy nauki i obrazovaniya. – Modern problems of science and education. 2015;6. Available at: www.science-education.ru/ru/article/ view?id=22788. Accessed September 13, 2018. (In Russ.).
5. Alix-Panabieres C., Pantel K. Detection and characterization of disseminating cancer cells in patients with solid epithelial malignancies. Haematopoiesis Immunology. 2012;10(1):79-93. https://doi.org/10.1007/s10555-012-9370-z
6. Bzhadug O. B., Grivtsova L. Yu., Tupitsyn N. N., Tyulyandin S. A. Vestnik Rossiyskogo onkologicheskogo nauchnogo tsentra imeni N. N. Blokhina RAMN. – Bulletin of Blokhin Russian Cancer Research Center of RAMS. 2007;3:19-22. (In Russ.).
7. Kit O. I., Novikova I. A., Bakhtin A. V., Nikipelova E. A., Shatova Yu. S., Gabaraeva V. M., Nistratova O. V. Mezhdunarodnyy zhurnal eksperimental’nogo obrazovaniya. – International journal of experimental education. 2013;11:37-39. (In Russ.).
8. Budd G. T., Cristofanilli M., Ellis M. J. Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin. Cancer. Res. 2006;12:6403- 6409. https://doi.org/10.1158/1078-0432.CCR-05-1769

Keywords: circulating tumor cells, breast cancer

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy